Matthew D Mattson

age ~60

from Brea, CA

Get Report

Connected to:

Matthew Mattson Phones & Addresses

1223 El Encanto Dr, Brea, CA 92821 • 7142735041
Anaheim, CA
Muskogee, OK
Flatwoods, LA
Ann Arbor, MI
Orange, CA

Work

Position:

Professional/Technical

Education

Degree:

High school graduate or higher

Emails

m***[email protected]

Resumes

Manager, System Design & Integration At Quantason

view source

Position:

Manager, System Design & Integration at Quantason, Chief Technology Officer at Visdex Corporation, Visiting Scientist in Chemical Engineering Department at California Institute of Technology

Location:

Greater Los Angeles Area

Industry:

Research

Work:

Quantason since Feb 2013
Manager, System Design & Integration
Visdex Corporation since 2010
Chief Technology Officer
California Institute of Technology since 2008
Visiting Scientist in Chemical Engineering Department
University of California, San Francisco Jun 2008 - May 2010
Postdoctoral Scholar

Education:

California Institute of Technology 2002 - 2008
Doctor of Philosophy (PhD), Applied Physics California Institute of Technology 2002 - 2004
Master of Science (MS), Applied Physics Marshall University 1998 - 2002
Bachelor of Science (BS), Physics

Honor & Awards:

• National Eye Institute Travel Grant – Association for Research and Vision Annual Conference - 2005 • Special Institution Fellowship – California Institute of Technology, Pasadena, CA - 2002-2003 • Summa Cum Laude and University Honors – Marshall University, Huntington, WV - 2002 • Marshall University NASA Space Grant: NASA Group Student Scholarship - 2000-2001 • Mathematics Department Student of the Year – Marshall University, Huntington, WV - 2000-2001 • John Marshall Scholarship – Marshall University, Huntington, WV - 1998-2002 • Eagle Scout, Gloucester, VA - 1994

Languages:

Spanish

Project Engineer At Acco Engineered Systems | Leed Ap Bd+C, Cem, Ceng

view source

Position:

Project Engineer at ACCO Engineered Systems

Location:

San Francisco Bay Area

Industry:

Mechanical or Industrial Engineering

Work:

ACCO Engineered Systems - San Leandro, CA
Project Engineer
ACCO Engineered Systems - Costa Mesa, CA 2010 - 2013
Design Engineer
N.V. Heathorn - San Leandro, CA 2008 - 2010
Project Engineer
C. Overaa & Co. - Richmond, Ca 2008 - 2009
Project Engineer
J.R. Filanc - Escondido, Ca May 2007 - Aug 2007
Project Engineer Intern

Education:

California State University-Sacramento 2004 - 2009
Bachelors of Science, Mechanical Engineering, Business Administration

Languages:

Arabic

Certifications:

Certified Energy Manager (C.E.M), Association of Energy Engineers
Leadership in Energy and Environmental Design Accredited Professional (LEED AP BD+C), U.S. Green Building Council
Chartered Engineer (CEng), Institution of Mechanical Engineers (IMechE)
Engineer In Training (E.I.T.), California Board for Professional Engineers and Land Surveyors

Name / Title

Company / Classification

Phones & Addresses

Matthew Mattson
Director Information Technology

City of Los Angeles
Library

1005 W 64 St, Los Angeles, CA 90044
3237894800

Us Patents

Photochemical Therapy To Affect Mechanical And/Or Chemical Properties Of Body Tissue
view source
US Patent:

8414911, Apr 9, 2013
Filed:

Oct 24, 2007
Appl. No.:

11/923575
Inventors:

Matthew S. Mattson - Pasadena CA, US
Julia A. Kornfield - Pasadena CA, US
Daniel M. Schwartz - San Francisco CA, US
Robert K. Maloney - Palisades CA, US
Robert H. Grubbs - South Pasadena CA, US
Assignee:

The Regents of the University of California - Oakland CA
California Institute of Technology - Pasadena CA
International Classification:

A61F 2/00
A61K 31/74
US Classification:

424427, 424 7808
Abstract:

The disclosure concerns altering the mechanical and/or chemical property of a body tissue, particularly an ocular tissue. In specific cases, it concerns altering or stabilizing the shape of the cornea, such as in a subject suffering or at risk for ectasia or keratoconus. In other specific cases, it concerns strengthening the sclera in a subject suffering or at risk for myopia. The invention employs light irradiation of a photoactivatable compound, such as one that applies crosslinking to the tissue, for example.

Light Delivery Device And Related Compositions, Methods And Systems
view source
US Patent:

20120310141, Dec 6, 2012
Filed:

May 4, 2012
Appl. No.:

13/464950
Inventors:

Julia A. KORNFIELD - Pasadena CA, US
Matthew S. MATTSON - Pasadena CA, US
Joyce HUYNH - Westminster CA, US
International Classification:

A61K 31/352
A61P 27/02
C12Q 1/02
C07D 311/82
A61N 5/06
A61M 37/00
US Classification:

604 20, 607 88, 607 90, 514454, 435 29, 549223
Abstract:

Devices and systems for delivering light to a target are described. Methods of using such light delivery device and system are also described. A method of using a photosensitizing compound with the light delivery device is also described.

Pyridonyl Guanidine F1F0-Atpase Inhibitors And Therapeutic Uses Thereof
view source
US Patent:

20140051727, Feb 20, 2014
Filed:

Dec 8, 2011
Appl. No.:

13/992254
Inventors:

Gary D. Glick - Ann Arbor MI, US
Alexander R. Hurd - Ann Arbor MI, US
Matthew N. Mattson - Santa Clara CA, US
Clarke B. Taylor - Ann Arbor MI, US
Chad A. Van Huis - Hartland MI, US
Assignee:

Lycera Corporation - Ann Arbor MI
International Classification:

C07D 213/75
C07D 401/12
C07D 213/76
C07D 413/12
C07D 405/12
US Classification:

514335, 546291, 514346, 5462721, 514340, 5462821, 514336, 546306, 514353, 546261, 5462744, 514341, 435184
Abstract:

The invention provides pyridonyl guanidine compounds that inhibit FF-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

Light Delivery Device And Related Compositions, Methods And Systems
view source
US Patent:

20150359668, Dec 17, 2015
Filed:

Jul 10, 2015
Appl. No.:

14/797063
Inventors:

- PASADENA CA, US
Matthew S. MATTSON - PASADENA CA, US
Joyce HUYNH - WESTMINSTER CA, US
International Classification:

A61F 9/008
A61K 41/00
A61F 9/00
Abstract:

Devices and systems for delivering light to a target are described. Methods of using such light delivery device and system are also described. A method of using a photosensitizing compound with the light delivery device is also described.

Pyridonyl Guanidine F1F0-Atpase Inhibitors And Therapeutic Uses Thereof
view source
US Patent:

20150335625, Nov 26, 2015
Filed:

Apr 1, 2015
Appl. No.:

14/675832
Inventors:

- Ann Arbor MI, US
Alexander R. Hurd - Ann Arbor MI, US
Matthew N. Mattson - Santa Clara CA, US
Clarke B. Taylor - Ann Arbor MI, US
Chad A. Van Huis - Hartland MI, US
International Classification:

A61K 31/44
A61K 31/4433
A61K 31/444
A61K 31/4439
Abstract:

The invention provides pyridonyl guanidine compounds that inhibit FF-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

N-Sulfonylated Tetrahydroquinolines And Related Bicyclic Compounds For Inhibition Of Rorgamma Activity And The Treatment Of Disease
view source
US Patent:

20140088094, Mar 27, 2014
Filed:

Nov 8, 2011
Appl. No.:

13/883419
Inventors:

Gary D. Glick - Ann Arbor MI, US
Peter L. Toogood - Ann Arbor MI, US
Arthur Glenn Romero - Chesterfield MO, US
Chad A. Van Huis - Hartland MI, US
Thomas Daniel Aicher - Ann Arbor MI, US
Carl Kaub - San Mateo CA, US
Matthew N. Mattson - Santa Clara CA, US
William David Thomas - San Jose CA, US
Erik Krogh-Jespersen - Palo Alto CA, US
Zhan Wang - San Jose CA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Lycera Corporation - Ann Arbor MI
International Classification:

C07D 231/56
C07D 409/12
C07D 401/12
C07D 413/06
C07D 417/12
C07D 405/12
C07D 403/12
C07D 265/36
C07D 215/58
C07D 413/12
US Classification:

5142305, 546153, 514312, 544405, 51425505, 544355, 514249, 5483611, 514407, 5483625, 548181, 514365, 544131, 5142345, 5462757, 514338, 544105, 435375
Abstract:

The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.